论文部分内容阅读
近年来许多实验及临床研究证实清栓酶具有抗凝、溶栓、去纤、降低血小板功能及改善微循环的作用,是治疗血栓性疾病的新药.临床应用此药治疗心、脑血管疾病收到良好的效果.本文重点观察清栓酶对冠心病患者前列腺素代谢产物血栓素 A_2、前列腺环素及血小板聚集性的影响,为探讨其药理作用提供可靠的理论依据.一、对象与方法:1、分组:(1)冠心病组11例(男9例、女2例)平均年龄53岁,不稳定心绞痛8例,稳定心绞痛3例。(2)、正常对照组:44例(男30例、女14例)平
In recent years, many experimental and clinical studies have confirmed that Qing thrombin enzyme with anticoagulant, thrombolysis, defibrillating, lower platelet function and improve microcirculation, is a new drug for the treatment of thrombotic diseases .Clinical application of this medicine for the treatment of cardiovascular and cerebrovascular diseases To good effect.This article focuses on the observation of Qing thrombin in patients with coronary heart disease prostaglandin metabolites thromboxane A 2, prostacyclin and platelet aggregation, in order to explore its pharmacological effects provide a reliable theoretical basis.Material and methods: 1, grouping: (1) Coronary heart disease group 11 cases (9 males and 2 females) with an average age of 53 years, 8 cases of unstable angina and 3 cases of stable angina. (2), normal control group: 44 cases (30 males and 14 females) were flat